RSS   Newsletter   Contact   Advertise with us
Post Online Media
Teva   Non-GAAP EPS is expected to be $1.34-$1.44

Teva expects Q4 revenues to be $6.2-$6.5 billion

TevaTeva reaffirmed its full-year 2016 outlook: revenues for full year 2016 are expected to be $21.6-$21.9 billion and revenues for the fourth quarter of year 2016 are expected to be $6.2-$6.5 billion.

Non-GAAP EPS for 2016 is expected to be $5.10-$5.20, based on a weighted average number of shares of 1,020 million.

READ MORE Teva Pharma Q2 revenues down 2% to $4.97 billion, guidance up to EPS $5.15 to $5.40

Non-GAAP EPS is expected to be $1.34-$1.44, based on a weighted average number of shares of 1,077 million.

Cash flow from operating activities for 2016 is expected to be $4.8-$5.0 billion; cash flow from operating activities for the fourth quarter of 2016 is expected to be $1.0-$1.2 billion.




What to read next





More inside POST
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy